Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

doi:10.1158/1078-0432.CCR-11-2294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2012

Hurvitz Sara A, Betting David J, Stern Howard M, Quinaux Emmanuel, Stinson Jeremy, Seshagiri Somasekar, Zhao Ying, Buyse Marc, Mackey John, Driga Adrian, Damaraju Sambasivarao, Sliwkowski Mark X, Robert Nicholas J, Valero Vicente, Crown John, Falkson Carla, Brufsky Adam, Pienkowski Tadeusz, Eiermann Wolfgang, Martin Miguel, Bee Valerie, Marathe Omkar, Slamon Dennis J, Timmerman John M

Abstract excerpt

PURPOSE: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcγ receptors (FcγR) on leukocytes may contribute to its antitumor effects. Single-nucleotide polymorphisms (SNP) in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131, respectively, and affect binding of antibodies to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Breast Neoplasms

Share to Gene Frequency

Share to Receptors, IgG

Share to Trastuzumab

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 22504044
DOI: 10.1158/1078-0432.CCR-11-2294
PMCID: PMC3821872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.PMID 22504044Read ↗

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.Semantic proximity Read ↗

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Semantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Semantic proximity Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.Semantic proximity Read ↗

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.Semantic proximity Read ↗

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.Semantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.